Alex H. Chen

Alex H. Chen

Auto-generated profile, based on publicly available information

Alex H. Chen

Perelman School of Medicine, University of Pennsylvania 3400 Spruce Street

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2024 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
SPSushant Patkar
Sushant Patkar
ACAlex Chen
Alex Chen
ABAlina Basnet
Alina Basnet
ABAmber Bixby
Amber Bixby
RRRahul Rajendran
Rahul Rajendran
TJTamara Jamaspishvili
Tamara Jamaspishvili
Immune checkpoint inhibitors (ICI) have become integral to treatment of non-small cell lung cancer (NSCLC). However, reliable biomarkers predictive of immunotherapy efficacy are limited. Here, we introduce HistoTME, a novel weakly supervised deep learning approach to infer the tumor microenvironment (TME) composition directly from histopathology images of NSCLC patients. We show that HistoTME accurately predicts the expression of 30 distinct cell type-specific molecular signatures directly from whole slide images, achieving an average Pearson correlation of 0.5 with the ground truth on independent tumor cohorts. Furthermore, we find that HistoTME-predicted microenvironment signatures and their underlying interactions improve prognostication of lung cancer patients receiving immunotherapy, achieving an AUROC of 0.75 [95% CI: 0.61-0.88] for predicting treatment responses following first-line ICI treatment, utilizing an external clinical cohort of 652 patients. Collectively, HistoTME presents an effective approach for interrogating the TME and predicting ICI response, complementing PD-L1 expression, and bringing us closer to personalized immuno-oncology.

12 June 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SPSushant Patkar
Sushant Patkar
ACAlex H Chen
Alex H Chen
ABAlina Basnet
Alina Basnet
ABAmber Bixby
Amber Bixby
RRRahul Rajendran
Rahul Rajendran
TJTamara Jamaspishvili
Tamara Jamaspishvili
Immune checkpoint inhibitors (ICI) have become integral to treatment of non-small cell lung cancer (NSCLC). However, reliable biomarkers predictive of immunotherapy efficacy are limited. Here, we introduce HistoTME, a novel weakly supervised deep learning approach to infer the tumor microenvironment (TME) composition directly from histopathology images of NSCLC patients. We show that HistoTME accurately predicts the expression of 30 distinct cell type-specific molecular signatures directly from whole slide images, achieving an average Pearson correlation of 0.5 with the ground truth on independent tumor cohorts. Furthermore, we find that HistoTME-predicted microenvironment signatures and their underlying interactions improve prognostication of lung cancer patients receiving immunotherapy, achieving an AUROC of 0.75[95% CI: 0.61-0.88] for predicting treatment responses following first-line ICI treatment, utilizing an external clinical cohort of 652 patients. Collectively, HistoTME presents an effective approach for interrogating the TME and predicting ICI response, complementing PD-L1 expression, and bringing us closer to personalized immuno-oncology.

26 October 2026 in ACS Chemical Biology
Verified
Journal Article
Closed access
ACAlex H. Chen
Alex H. Chen
YZYingzhao Zhao
Yingzhao Zhao
SKSoojin Kwon
Soojin Kwon
RVRashmi Vyas
Rashmi Vyas
RGRaymond F. Gamache
Raymond F. Gamache
MFMichael D. Farwell
Michael D. Farwell